Experimental drugs for fallopian cancer: promising agents in the clinical trials and key stumbling blocks for researchers

References

• Berek JS, Renz M, Kehoe S, et al. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update First published. Int J Gynaecol Obstet. 2021 20 October. 10.1002/ijgo.13878).
   Web of Science ®Google Scholar
• Stasenko M, Fillipova O, William P. Tew fallopian tube carcinoma. J Oncol Practice. 2019;15(7):375–382.
   PubMed Web of Science ®Google Scholar
• Colombo N, Sessa C, du Bois A, et al. ESMO-ESGO ovarian cancer consensus conference working group. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. Ann Oncol. 2019 May 1;30(5):672–705. PMID: 31046081.
   PubMed Web of Science ®Google Scholar
• Dalmartello M, La Vecchia C, Bertuccio P, et al. European cancer mortality predictions for the year 2022 with focus on ovarian cancer. Ann Oncol. 2022;33(3):330–339. DOI:10.1016/j.annonc.2021.12.007.
   PubMed Web of Science ®Google Scholar
• Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–2496.
   PubMed Web of Science ®Google Scholar
• Tewari KS, Burger RA, Enserro D, et al. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. J Clin Oncol. 2019;37(26):26, 2317–2328.
   PubMed Web of Science ®Google Scholar
• Lynch HT, Watson P, Lynch JF, et al. Hereditary ovarian cancer. Heterogeneity in age at onset. Cancer. 1993;71(2 Suppl):573–581.
   PubMed Web of Science ®Google Scholar
• Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336(20):1401–1408.
   PubMed Web of Science ®Google Scholar
• Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006;30(2):230–236.
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Banerjee S, Pignata S. Management of platinum-resistant, relapsed epithelial ovarian cancer and new drug perspectives. J Clin Oncol. 2019;37(27):27, 2437–2448.
   PubMed Web of Science ®Google Scholar
• García García Y, Marín Alcalá M, Martínez Vila C. Anti-angiogenic therapy for ovarian cancer. Euro J Cancer Suppl. 2020;15:77–86. 10.1016/j.ejcsup.2020.02.003.
   Google Scholar
• Vergote I, du Bois A, Floquet A, et al. Overall survival results of AGO-OVAR16: a phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer. Gynecol Oncol. 2019;155(2):186–191.
   PubMed Web of Science ®Google Scholar
• Monk BJ, Poveda A, Vergote I, et al. Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): long-term survival, impact of ascites, and progression-free survival-2. Gynecol Oncol. 2016 Oct;143(1):27–34. Epub 2016 Aug 18. PMID: 27546885. (NCT01204749
   PubMed Web of Science ®Google Scholar
• Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial icon-6.
   Google Scholar
• Lee J-M, Moore RG, Ghamande SA, et al. Cediranib in combination with olaparib in patients without a germline BRCA1/2 mutation with recurrent platinum-resistant ovarian cancer: phase IIb CONCERTO trial. J clin oncol. 2020;38(15_suppl):6056–6056.
   Web of Science ®Google Scholar
• Liu JF, Brady MF, Matulonis UA, et al. A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer. J clin oncol. 2020;38(15_suppl):6003–6003).
   Web of Science ®Google Scholar
• Elyashiv O, Ledermann J, Parmar G, et al. ICON 9—an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapyInternational. Int J Gynecol Cancer 2021;31:134–138. NCT03278717. ;:.
   PubMed Web of Science ®Google Scholar
• Fuh KC, Bookman MA, Liu JF, et al. Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer. Gynecol Oncol. 2021 Nov;163(2):254–261. Epub 2021 Aug 30. PMID: 34474927. (NCT03639246
   PubMed Web of Science ®Google Scholar
• Randomized Phase I/II Study of AVB-S6-500 in combination with durvalumab (MEDI4736) in patients with platinum-resistant, recurrent epithelial ovarian cancer (2019-2022. NCT04019288.
   Google Scholar
• Anlotinib in patients with recurrent platinum-resistant or refractory ovarian carcinoma: a prospective, single-arm, single-center, phase II clinical study. J Clin Oncol. https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.6061
   Google Scholar
• A prospective, single-arm, multicenter, exploratory phase ii study to evaluate the efficacy and safety of anlotinib combined with carboplatin/paclitaxel as first-line treatment in patients with advanced ovarian cancer. (NCT04807166).
   Google Scholar
• Backes FJ, Wei L, Min Chen, et al. Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer. Gynecol Oncol. 2021;162(3):619–625.
   PubMed Web of Science ®Google Scholar
• Phase II study with safety lead-in of lenvatinib, pembrolizumab, and weekly paclitaxel for recurrent endometrial, epithelial ovarian, fallopian tube and primary peritoneal cancer. NCT04781088.
   Google Scholar
• Immunomodulation of the tumor microenvironment in high-grade serous ovarian cancer patients receiving pembrolizumab and lenvatinib monotherapy and combination therapy (NCT05114421).
   Google Scholar
• Markham A. Envafolimab: first Approval. Drugs. 2022 Feb;82(2):235–240. PMID: 35122636.
   PubMed Web of Science ®Google Scholar
• An open, single-arm clinical study of envafolimab, lenvatinib combined with VP-16 in the treatment of platinum-resistant recurrent epithelial ovarian cancer, primary fallopian tube cancer and primary peritoneal carcinoma (NCT05422183).
   Google Scholar
• Li J, Zhao X, Chen L, et al. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer. 2010 Oct 5;10(1):529. PMID: 20923544; PMCID: PMC2984425.
   PubMedGoogle Scholar
• Miao M, Deng G, Luo S, et al. A phase II study of apatinib in patients with recurrent epithelial ovarian cancer. Gynecol Oncol. 2018;148(2):286–290.
   PubMed Web of Science ®Google Scholar
• Lan CY, Wang Y, Xiong Y, et al. Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study. Lancet Oncol. 2018;19(9):1239–1246. Epub 2018 Aug 3. Erratum in: Lancet Oncol. 2018 Sep;19(9):e440. PMID: 30082170. (NCT04000295).
   PubMed Web of Science ®Google Scholar
• A randomized, double-blind, placebo-controlled, multi-center, phase iii clinical trial evaluating the efficacy and safety of fluzoparib±apatinib for maintenance treatment in patients with advanced ovarian cancer who have achieved effective response after first-line platinum-containing chemotherapy (NCT04229615).
   Google Scholar
• A phase 2 open label, randomised, controlled, multi-centre study to assess the efficacy and safety of fluzoparib combined with apatinib versus fluzoparib monotherapy in the treatment of relapsed ovarian cancer patients (NCT04517357).
   Google Scholar
• Camrelizumab combined with apatinib for recurrent platinum-resistant ovarian cancer: a phase 2 single-arm prospective study (NCT04068974).
   Google Scholar
• Eskens FA, de Jonge MJ, Bhargava P, et al. Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, −2, and −3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors. Clin Cancer Res. 2011 Nov 15;17(22):7156–7163. Epub 2011 Oct 5. PMID: 21976547.
   PubMed Web of Science ®Google Scholar
• Cowan M, Swetzig WM, Adorno-Cruz V, et al. Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial. Gynecol Oncol. 2021 Oct;163(1):57–63. Epub 2021 Aug 18. PMID: 34419285
   PubMed Web of Science ®Google Scholar
• Perez-Fidalgo JA, Ortega B, Simon S, et al. NOTCH signalling in ovarian cancer angiogenesis. Ann Transl Med. 2020 Dec;8(24):1705. PMID: 33490217; PMCID: PMC7812236
   PubMed Web of Science ®Google Scholar
• Fu S, Corr BR, Culm-Merdek K, et al. Phase Ib study of navicixizumab plus paclitaxel in patients with platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2022;19:JCO2101801. Epub ahead of print. PMID: 35439029. DOI:10.1200/JCO.21.01801
   Google Scholar
• An open label randomized study of navicixizumab plus paclitaxel and navicixizumab monotherapy in comparison to paclitaxel monotherapy in patients with platinum-resistant epithelial ovarian, primary peritoneal, or fallopian tube cancer. NCT05043402. • The only phase III, ongoing trial which will evaluate Navicixumab both as monotherapy and in combination with Paclitaxel, in the platinum-resistant cohort
   Google Scholar
• Krasner CN, Campos SM, Young CL, et al. Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer. Gynecol Oncol. 2021 Sep;162(3):661–666. Epub 2021 Jul 7. PMID: 34243976
   PubMed Web of Science ®Google Scholar
• Herzog TJ, Ison G, McKee a, et al. fda ovarian cancer clinical trial endpoints workshop: a society of gynecologic oncology white paper. Gynecol Oncol. 2017;147(1):3–10.
   PubMed Web of Science ®Google Scholar
• Hartnett EG, Knight J, Radolec M, et al. Immunotherapy advances for epithelial ovarian cancer. Cancers (Basel). 2020 Dec 11;12(12):3733. PMID: 33322601; PMCID: PMC7764119.
   PubMed Web of Science ®Google Scholar
• Maiorano BA, Maiorano MFP, Lorusso D, et al. Ovarian cancer in the era of immune checkpoint inhibitors: state of the art and future perspectives. Cancers (Basel). 2021;13:(17)4438.
   PubMed Web of Science ®Google Scholar
• Hamanishi J, Mandai M, Iwasaki M, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A. 2007;104(9):3360–3365.
   PubMed Web of Science ®Google Scholar
• Leary A, Tan D, Ledermann J, Immune checkpoint inhibitors in ovarian cancer: where do we stand? Ther Adv Med Oncol. January 2021;13:175883592110398.
   Web of Science ®Google Scholar
• Jimenez-Sanchez A, Cybulska P, Mager KL, et al. Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy. Nat Genet. 2020;52(6):582–593.
   PubMed Web of Science ®Google Scholar
• Leary A, Genestie C, Blanc-Durand F, et al. Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer. Cancer Immunol Immunother. 2021;70(2):519–531.
   PubMed Web of Science ®Google Scholar
• Matulonis UA, Shapira-Frommer R, Santin AD, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 Study. Ann Oncol. 2019;30(7):1080–1087.
   PubMed Web of Science ®Google Scholar
• Varga A, Piha-Paul S, Ott PA, et al. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028. Gynecol Oncol. 2019;152(2):243–250.
   PubMed Web of Science ®Google Scholar
• Chung HC, Piha-Paul SA, Lopez-Martin J, et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies. J Thorac Oncol. 2020 Apr;15(4):618–627. Epub 2019 Dec 20. PMID: 31870883
   PubMed Web of Science ®Google Scholar
• Lee EK, Xiong N, Cheng SC, et al. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: a phase 2 clinical trial. Gynecol Oncol. 2020 Oct;159(1):72–78. Epub 2020 Aug 6. PMID: 32771276. (NCT02865811
   PubMed Web of Science ®Google Scholar
• A phase 3, multicenter, open-label, randomized study of nemvaleukin alfa in combination with pembrolizumab versus investigator’s choice chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. (ARTISTRY-7) (NCT05092360). • The only phase III trial combining Pembrolizumab and Nemvaleukin Alfa
   Google Scholar
• Phase 2 study of pembrolizumab, DPX-survivac vaccine and cyclophosphamide in advanced ovarian, primary peritoneal or fallopian tube cancer (2018, 2024) (NCT03029403.
   Google Scholar
• Hamanishi J, Takeshima N, Katsumata N, et al. Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in Japan (NINJA). J Clin Oncol. 2021 Nov 20;39(33):3671–3681. Epub 2021 Sep 2. PMID: 34473544; PMCID: PMC8601279.
   PubMed Web of Science ®Google Scholar
• Zamarin D, Burger RA, Sill MW, et al. Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian Cancer: an NRG oncology study. J Clin Oncol. 2020;38(16):1814–1823. Epub 2020 Apr 10. Erratum in: J Clin Oncol. 2020 Aug 10;38(23):2702. PMID: 32275468; PMCID: PMC7255977.
   PubMed Web of Science ®Google Scholar
• Liu JF, Herold C, Gray KP, et al. Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer: a phase 2 clinical trial. JAMA Oncol. 2019;5(12):1731–1738.
   PubMed Web of Science ®Google Scholar
• Liu J, Gaillard S, Hendrickson AW, et al. An open-label phase II study of dostarlimab (TSR-042), bevacizumab (bev), and niraparib combination in patients (pts) with platinum-resistant ovarian cancer (PROC): cohort A of the OPAL trial. Gynecol Oncol. 2021;162(Supplement 1):S17–S18.
   Google Scholar
• Randomized phase III trial on NIraparib-TSR-042 (Dostarlimab) vs physician’s choice chemotherapy in recurrent, ovarian, fallopian tube or primary peritoneal cancer patients not candidate for platinum retreatment: nItCHE Trial (MITO 33). NCT04679064.
   Google Scholar
• ENGOT-0V44 The FIRST (First-line ovarian cancer treatment with niraparib plus TSR-042) study: a randomized, double-blind, phase 3 comparison of platinum-based therapy with TSR-042 and niraparib versus standard of care platinum-based therapy as first-line treatment of stage III or IV Nonmucinous epithelial ovarian cancer. NCT03602859.
   Google Scholar
• Disis ML, Taylor MH, Kelly K, et al. Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial. JAMA Oncol. 2019;5(3):393.
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Fujiwara K, Ledermann JA, et al. Avelumab alone or in combination with pegylated liposomal doxorubicin vs. pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: primary and biomarker analysis of the phase III JAVELIN ovarian 200 trial. Gynecol Oncol. 2019;154:21–22.
   Web of Science ®Google Scholar
• Ledermann JA, Colombo N, Oza AM, et al. Avelumab in combination with and/or following chemotherapy vs chemotherapy alone in patients with previously untreated epithelial ovarian cancer: results from the phase 3 javelin ovarian 100 trial. Gynecol Oncol. 2020;159:13–14.
   PubMed Web of Science ®Google Scholar
• Moore KN, Bookman M, Sehouli J, et al. Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050/GOG 3015/ENGOT-OV39). J Clin Oncol. 2021;39(17):1842–1855. Epub 2021 Apr 23. Erratum in: J Clin Oncol. 2021 Jul 20;39(21):2420. PMID: 33891472; PMCID: PMC8189598.
   PubMed Web of Science ®Google Scholar
• A randomized phase 2 trial of atezolizumab (MPDL3280A), SGI-110 and CDX-1401 vaccine in recurrent ovarian cancer (NCT03206047).
   Google Scholar
• BEACON - A phase II study of bevacizumab, atezolizumab and cobimetinib in patients with recurrent platinum resistant high grade serous ovarian cancer. NCT03363867.
   Google Scholar
• Drew Y, Kaufman B, Banerjee S, et al. Phase II study of olaparib + durvalumab (MEDIOLA): updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC) (NCT02734004)|. Ann Oncol. 2019 october 01;30(supplement 5):v485–v486.
   Google Scholar
• A phase III randomised, double-blind, placebo-controlled, multicentre study of durvalumab in combination with chemotherapy and bevacizumab, followed by maintenance durvalumab, bevacizumab and olaparib in newly diagnosed advanced ovarian cancer patients (DUO-O). NCT03737643.
   Google Scholar
• Phase II study of ipilimumab monotherapy in recurrent platinum-sensitive ovarian cancer-study results.
   Google Scholar
• A phase 1-2 study of the combination of olaparib and tremelimumab, in BRCA1 and BRCA2 Mutation Carriers With Recurrent Ovarian Cancer (NCT02571725).
   Google Scholar
• Ramus SJ, Gayther SA. The contribution of BRCA1 and BRCA2 to ovarian cancer. Mol Oncol. 2009 Apr;3(2):138–150. Epub 2009 Feb 10. PMID: 19383375; PMCID: PMC5527889.
   PubMed Web of Science ®Google Scholar
• Coleman RL, Fleming GF, Brady MF, et al. Veliparib with First-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med. 2019 Dec 19;381(25):2403–2415. Epub 2019 Sep 28. PMID: 31562800; PMCID: PMC6941439.
   PubMed Web of Science ®Google Scholar
• De Bono J, Ramanathan RK, Mina L, et al. Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers. Cancer Discov. 2017;7(6):620–629.
   PubMed Web of Science ®Google Scholar
• Dhawan MS, Bartelink IH, Aggarwal RR, et al. Differential toxicity in patients with and without DNA repair mutations: phase I study of carboplatin and talazoparib in advanced solid tumors. Clin Cancer Res. 2017;23(21):6400–6410.
   PubMed Web of Science ®Google Scholar
• POSITION: a pilot study of induction PARP inhibition in ovarian cancer. NCT02316834.
   Google Scholar
• Ray-Coquard I, Pautier P, Pignata S, et al. PAOLA-1 investigators. olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019 Dec 19;381(25):2416–2428. PMID: 31851799.
   PubMed Web of Science ®Google Scholar
• Randomized study of paclitaxel-carboplatin followed by niraparib compared to paclitaxel-carboplatin-bevacizumab followed by Niraparib+Bevacizumab in patients with advanced ovarian cancer, following a front-line complete surgery (NCT05183984).
   Google Scholar
• Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer—A randomized controlled chemotherapy-free study. PHASE II AVANOVA2 (2015-2021). NCT02354131.
   Google Scholar
• A single-arm, prospective, open-label, phase II study to evaluate the efficacy and safety of niraparib combined with bevacizumab in platinum refractory/resistant recurrent ovarian, fallopian tube or peritoneal cancer. (AVANIRA3) (NCT04556071).
   Google Scholar
• Randomised phase II Trial of Olaparib, Chemotherapy or Olaparib and Cediranib in Patients With Platinum-resistant Ovarian Cancer (NCT03117933).
   Google Scholar
• Colombo N, Tomao F, Benedetti Panici P, et al. BAROCCO study group. Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer. Gynecol Oncol. 2022 Mar;164(3):505–513. Epub 2022 Jan 19. PMID: 35063281
   PubMed Web of Science ®Google Scholar
• Lheureux S, Oaknin A, Garg S, et al. EVOLVE: a multicenter open-label single-arm clinical and translational phase II trial of cediranib plus olaparib for ovarian cancer after PARP inhibition progression. Clin Cancer Res. 2020 Aug 15;26(16):4206–4215. Epub 2020 May 22. PMID: 32444417.
   PubMed Web of Science ®Google Scholar
• A single-arm phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive recurrent ovarian cancer patients previously treated with a PARP inhibitor (NCT04734665).
   Google Scholar
• Shen J, Zhao W, Ju Z, et al. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res. 2019;79(2):311–319.
   PubMed Web of Science ®Google Scholar
• Wang Z, Sun K, Xiao Y, et al. Niraparib activates interferon signaling and potentiates anti–PD-1 antibody efficacy in tumor models. Sci Rep. 2019;9(1):1853.
   PubMed Web of Science ®Google Scholar
• Jiao S, Xia W, Yamaguchi H, et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res. 2017;23(14):3711–3720.
   PubMed Web of Science ®Google Scholar
• Lee JM, Cimino-Mathews A, Peer CJ, et al. Safety and clinical activity of the programmed death-ligand 1 inhibitor durvalumab in combination with poly (ADP-Ribose) polymerase inhibitor olaparib or vascular endothelial growth factor receptor 1–3 inhibitor cediranib in women’s cancers: a dose-escalation, phase I study. JCO. 2017;35:2193–2202.
   PubMed Web of Science ®Google Scholar
• Lampert EJ, Zimmer A, Padget M, et al. Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study. Clin Cancer Res. 2020;26(16):4268–4279.
   PubMed Web of Science ®Google Scholar
• Lee JY, Kim BG, Kim JW, et al. Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial. J Gynecol Oncol. 2022 Jul;33(4):e45. Epub 2022 Mar 4. PMID: 35320892; PMCID: PMC9250853. (NCT03699449
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA, Waggoner S, Vidal GA, et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol. 2019;5(8):1141.
   PubMed Web of Science ®Google Scholar
• ENGOT-0V44 The FIRST (First-line ovarian cancer treatment with niraparib plus TSR-042) study: a randomized, double-blind, phase 3 comparison of platinum-based therapy with TSR-042 and niraparib versus standard of care platinum-based therapy as first-line treatment of Stage III or IV. Nonmucinous Epithelial Ovarian Cancer (NCT03602859.
   Google Scholar
• A phase Ib study of the oral PARP inhibitor niraparib with the intravenous PI3K inhibitor copanlisib for recurrent endometrial and recurrent ovarian, primary peritoneal, or fallopian tube cancer (2019-2022).
   Google Scholar
• Lui GYL, Shaw R, Schaub FX, et al. BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer. EBioMedicine. 2020 Oct;60:102988. Epub 2020 Sep 11. PMID: 32927276; PMCID: PMC7494677 doi: 10.1016/j.ebiom.2020.102988
   PubMed Web of Science ®Google Scholar
• Phase ll study of a BET inhibitor, ZEN003694, combined with a PARP inhibitor, talazoparib, in patients with recurrent ovarian cancer. NCT05071937.
   Google Scholar
• BrUOG 390: neoadjuvant treatment with talazoparib for women with newly diagnosed, advanced ovarian cancer associated with a mutation in BRCA1 or BRCA2 (mBRCA) (2021-2027). NCT04598321.
   Google Scholar
• NOW. Neoadjuvant olaparib window trial in newly diagnosed BRCA-mutant ovarian cancer. (NCT03943173). 2019-2022 [cited 2022 Dec 5]. https://www.clinicaltrials.gov/ct2/show/NCT03943173
   Google Scholar
• Niraparib maintenance in patients with advanced ovarian cancer at neoadjuvant setting - a phase 2, single-arm trial (NEOPRIMA Trial). NCT04284852.
   Google Scholar
• The NUVOLA TRIAL: neoadjuvant chemotherapy in unresectable oVarian cancer with OLAparib and weekly carboplatin plus paclitaxel: a phase II open-label multicentre study (NCT04261465).
   Google Scholar
• Aithal A, Rauth S, Kshirsagar P, et al. MUC16 as a novel target for cancer therapy. Expert Opin Ther Targets. 2018;22(8):675–686.
   PubMed Web of Science ®Google Scholar
• Lee D-H, Choi S, Park Y, et al. Mucin1 and Mucin16: therapeutic targets for cancer therapy. Pharmaceuticals. 2021;14(10):1053.
   Web of Science ®Google Scholar
• Berek JS, Taylor PT, Gordon A, et al. Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol. 2004;22(17):3507–3516.
   PubMed Web of Science ®Google Scholar
• Berek J, Taylor P, McGuire W, et al. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol. 2009;27(3):418–425.
   PubMed Web of Science ®Google Scholar
• A double-blind, placebo-controlled, multicenter clinical trial of intravenous OvaRex® MAb-B43.13 as post chemotherapy consolidation for epithelial carcinoma of ovarian, tubal or peritoneal origin. (NCT00050375).
   Google Scholar
• Battaglia A, Buzzonetti A, Fossati M, et al. Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients. Cancer Immunol Immunother. 2020;69(3):383–397.
   PubMed Web of Science ®Google Scholar
• A multicenter phase 3, double-blind, placebo-controlled study comparing chemo-immunotherapy (paclitaxel-carboplatin- oregovomab) vs chemotherapy (paclitaxel-carboplatin- placebo) in patients with advanced epithelial ovarian, fallopian tube or peritoneal carcinoma. (NCT04498117), FLORA-5. (2020-2027). https://clinicaltrials.gov/ct2/show/NCT04498117
   Google Scholar
• Phase 1b/2, single arm clinical trial to evaluate the safety and activity of oregovomab and bevacizumab, paclitaxel carboplatin as a combinatorial strategy in subjects with BRCA-wild type platinum sensitive recurrent ovarian cancer. NCT04938583.
   Google Scholar
• A phase Ib/IIa clinical trial to evaluate the safety and activity of oregovomab and nivolumab as a combinatorial immunotherapy strategy in patients with recurrent epithelial cancer of ovarian, tubal or peritoneal origin. NCT03100006.
   Google Scholar
• A phase I/II clinical trial to evaluate platinum-based chemotherapy, oregovomab and nivolumab in patients with platinum sensitive recurrent epithelial cancer of ovarian, tubal or peritoneal origin. NCT04620954.
   Google Scholar
• Phase 2, single arm clinical trial to evaluate the safety and activity of oregovomab and niraparib as a combinatorial immune priming strategy in subjects with platinum sensitive. Recurrent Ovarian Cancer (NCT05335993.
   Google Scholar
• A phase II study of oregovomab and PLD in PARP inhibitor resistant ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment. NCT05407584.
   Google Scholar
• Phase 1/2 study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) administered in combination with cemiplimab or REGN4018 (MUC16xCD3) (2020-2026). NCT04590326.
   Google Scholar
• A phase 1/2 Study of REGN4018 (A MUC16xCD3 Bispecific Antibody) administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer (2018-2024). NCT03564340.
   Google Scholar
• Kong A, Mehanna H. WEE1 inhibitor: clinical development. Curr Oncol Rep. 2021 Jul 16;23(9):107. PMID: 34269904; PMCID: PMC8285350.
   PubMed Web of Science ®Google Scholar
• Lheureux S, Cristea MC, Bruce JP, et al. Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021 Jan 23;397(10271):281–292. PMID: 33485453.
   PubMed Web of Science ®Google Scholar
• Moore KN, Chambers SK, Hamilton EP, et al. Adavosertib with chemotherapy in patients with primary platinum-resistant ovarian, fallopian tube, or peritoneal cancer: an open-label, four-arm, phase II study. Clin Cancer Res. 2022 Jan 1;28(1):36–44. Epub 2021 Oct 13. PMID: 34645648.
   PubMed Web of Science ®Google Scholar
• Leijen S, van Geel RM, Sonke GS, et al. Phase II study of WEE1 Inhibitor AZD1775 plus carboplatin in patients with TP53-mutated ovarian cancer refractory or resistant to first-line therapy within 3 months. J Clin Oncol. 2016 Dec 20;34(36):4354–4361. Epub 2016 Oct 28. PMID: 27998224.
   PubMed Web of Science ®Google Scholar
• A randomized placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with AZD 1775 (MK 1775) in women with recurrent, platinum resistant epithelial ovarian, primary peritoneal, or fallopian tube cancers. ((NCT02151292.
   Google Scholar
• Oza AM, Estevez-Diz M, Grischke EM, et al. A biomarker-enriched, randomized phase II trial of adavosertib (AZD1775) plus paclitaxel and carboplatin for women with platinum-sensitive TP53-mutant ovarian cancer. Clin Cancer Res. 2020 Sep 15;26(18):4767–4776. Epub 2020 Jul 1. PMID: 32611648.
   PubMed Web of Science ®Google Scholar
• EFFORT. Efficacy of AZD1775 in Parp resistance; A randomized 2-arm, non-comparative phase 2 study of AZD1775 Alone or AZD1775 and olaparib in women with ovarian cancer who have progressed during PARP inhibition. NCT03579316. [cited 2022 Dec 5]. https://clinicaltrials.gov/ct2/show/NCT03579316
   Google Scholar
• https://ir.zentalis.com/news-releases/news-release-details/zentalis-pharmaceuticals-announces-positive-initial-clinical/ [cited 2022 Dec 5]
   Google Scholar
• A phase 1/2 dose-escalation and dose-expansion study of ZN-c3 in combination with niraparib in subjects with platinum-resistant ovarian cancer. NCT05198804.
   Google Scholar
• Phase I study of ZN-c3 and bevacizumab ± Pembrolizumab in metastatic CCNE1 amplified and TP53 mutant solid tumors. NCT05431582.
   Google Scholar
• Yap TA, O’Carrigan B, Penney MS, et al. Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as Monotherapy or in combination with carboplatin in patients with advanced solid tumors. J Clin Oncol. 2020 Sep 20;38(27):3195–3204. Epub 2020 Jun 22. PMID: 32568634; PMCID: PMC7499606.
   PubMed Web of Science ®Google Scholar
• Phase 2 Study of M6620 (VX-970) in combination with gemcitabine versus gemcitabine alone in subjects with platinum-resistant recurrent ovarian or primary peritoneal fallopian tube cancer. (NCT02595892).
   Google Scholar
• An open-label phase 1b study to determine the maximum tolerated and/or recommended phase 2 dose of the ATR inhibitor BAY 1895344 in combination with PARP inhibitor niraparib, in patients with recurrent advanced solid tumors and ovarian cancer. NCT04267939.
   Google Scholar
• Combination ATR and PARP Inhibitor (CAPRI) trial with AZD 6738 and olaparib in recurrent ovarian cancer. NCT03462342
   Google Scholar
• A study of the safety, tolerability, and pharamcokinetics of MORAb-003, a humanized monoclonal antibody, in subjects with advanced ovarian cancer. NCT00428766.
   Google Scholar
• A randomized, double-blind, placebo-controlled, phase 3 study to assess the efficacy and safety of weekly MORAb-003 in combination with carboplatin and taxane in subjects with platinum-sensitive ovarian cancer in first relapse. NCT00849667.
   Google Scholar
• A randomized, double blind, placebo-controlled study of the efficacy and safety oF MORAb-003(Farletuzumab) in combination with paclitaxel therapy in subjects with platinum-resistant or refractory relapsed ovarian cancer. NCT00738699.
   Google Scholar
• Vergote I, Armstrong D, Scambia G, et al. A randomized, double-blind, placebo-controlled, phase III study to assess efficacy and safety of weekly farletuzumab in combination with carboplatin and taxane in patients with ovarian cancer in first platinum-sensitive relapse. J Clin Oncol. 2016 Jul 1;34(19):2271–2278. Epub 2016 Mar 21. PMID: 27001568.
   PubMed Web of Science ®Google Scholar
• A randomized double-blind phase 3 trial comparing EC145 and pegylated liposomal doxorubicin (PLD/Doxil®/Caelyx®) in combination versus PLD in participants with platinum-resistant ovarian cancer. NCT01170650.
   Google Scholar
• Moore KN, Martin LP, O’Malley DM, et al. A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. Future Oncol. 2018 Jan;14(2):123–136. Epub 2017 Nov 3. PMID: 29098867
   PubMed Web of Science ®Google Scholar
• Moore KN, Martin LP, O’Malley DM, et al. Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase I expansion study. J Clin Oncol. 2017 Apr 1;35(10):1112–1118. Epub 2016 Dec 28. PMID: 28029313; PMCID: PMC5559878.
   PubMed Web of Science ®Google Scholar
• A phase 1b/2 study to evaluate the safety, tolerability and pharmacokinetics of mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin, pegylated liposomal doxorubicin, pembrolizumab, or Bevacizumab + Carboplatin, in adults with folate receptor alpha positive advanced epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (2015-2021). (NCT02606305) FORWARDII.•• Promising phase Ib/II trial evaluating different combinations with MIRV, in pre-selected patients
   Google Scholar
• SORAYA: a phase 3, single arm study of mirvetuximab soravtansine in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression. ( NCT04296890)• Ongoing phase III trial testing Mirvetuximab Soravstatine in platinum-resistant patients.
   Google Scholar
• Mirvetuximab soravtansine monotherapy in platinum-sensitive epithelial, peritoneal, and fallopian tube cancers (PICCOLO). NCT05041257. • Currently ongoing monotherapy, phase II trial evaluating MIRV in platinum-sensitive relapses
   Google Scholar
• Randomized, multicenter, open-label, phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with fra-positive recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second line platinum-based chemotherapy plus bevacizumab. NCT05445778.
   Google Scholar
• Dose escalation and expansion clinical study to evaluate the safety and efficacy of ELU001 in subjects who have advanced, recurrent or refractory FRa overexpressing tumors. NCT05001282.
   Google Scholar
• A phase 1 open-label, safety, pharmacokinetic and preliminary efficacy study of STRO-002, an anti-folate receptor alpha antibody drug conjugate, in combination with bevacizumab in patients with advanced epithelial ovarian cancer (including fallopian tube or primary peritoneal cancers). NCT05200364.
   Google Scholar
• A Phase 1b/2, first-in-human, dose escalation and expansion study of XMT-1536 in patients with solid tumors likely to express NaPi2b. NCT03319628.
   Google Scholar
• A phase 3, randomized, double-blind,placebo-controlled, multicenter study of upifitamab rilsodotin (XMT-1536) as post-platinum maintenance therapy for participants with recurrent, platinum-sensitive, ovarian cancer (UP-NEXT). (NCT05329545).
   Google Scholar
• An open-label, multicenter, dose escalation and expansion modular, umbrella master study of upifitamab rilsodotin in combination with other agent(s) in participants with high-grade serous ovarian cancer (UPGRADE). NCT04907968
   Google Scholar
• Thaker PH, Brady WE, Lankes HA, et al. A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 Nov;147(2):283–290.
   PubMed Web of Science ®Google Scholar
• A phase I/II study evaluating the dosing, safety, efficacy, and biological activity of intraperitoneal gen-1 (il-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer) administered in combination with Neoadjuvant Chemotherapy (NACT) in patients newly diagnosed with advanced epithelial ovarian, fallopian tube or primary peritoneal cancear (2018-2024). (NCT03393884).
   Google Scholar
• Phase 1-2 study of an immunotherapeutic vaccine, DPX-survivac with low dose cyclophosphamide in patients with surgically operable or advanced stage ovarian, fallopian tube or peritoneal cancer. [cited 2022 Jul 28] https://clinicaltrials.gov/ct2/show/NCT01416038
   Google Scholar
• Phase 1b study of extended dosing of an immunotherapeutic vaccine, DPX-survivac with low dose cyclophosphamide in patients with surgically operable or advanced stage ovarian, fallopian tube or peritoneal cancer [cited 2022 Jul 28]. https://clinicaltrials.gov/ct2/show/NCT03332576
   Google Scholar
• A Phase 1b/2 Study of an Immunotherapeutic Vaccine, DPX-survivac with low dose cyclophosphamide and epacadostat (INCB024360) in patients with recurrent ovarian cancer [cited 2022 Jul 28]. https://clinicaltrials.gov/ct2/show/NCT02785250
   Google Scholar
• A phase 2 study of pembrolizumab (MK-3475), DPX-survivac vaccine and low dose of cyclophosphamide combination in patients with advanced ovarian, primary peritoneal or fallopian tube cancer. (NCT03029403).
   Google Scholar
• T-cell therapy in combination with nivolumab, relatlimab and ipilimumab for patients with advanced ovarian-, fallopian tube- and primary peritoneal cancer [cited 2022 Jul 28]. https://clinicaltrials.gov/ct2/show/NCT04611126
   Google Scholar
• Haas AR, Tanyi JL, O’Hara MH, et al. Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers. Mol Ther. 2019 Nov 6;27(11):1919–1929. Epub 2019 Jul 30. PMID: 31420241; PMCID: PMC6838875.
   PubMed Web of Science ®Google Scholar
• A single-arm, open-label study to evaluate safety and efficacy of fully human B7H3 CAR-T in treating patients with recurrent malignant ovarian cancer [cited 2022 Jul 28]. https://clinicaltrials.gov/ct2/show/NCT05211557
   Google Scholar
• A phase I clinical study to evaluate the safety, tolerability, and efficacy of LCAR-M23, a CAR-T cell therapy targeting MSLN in patients with relapsed and refractory epithelial ovarian cancer [cited 2022 Jul 28]. https://clinicaltrials.gov/ct2/show/NCT04562298
   Google Scholar
• A phase 1 study to evaluate TAG72-targeting chimeric antigen receptor (CAR) T cells in patients with advanced epithelial ovarian. Cancer [cited 2022 Jul 28]. https://clinicaltrials.gov/ct2/show/NCT05225363
   Google Scholar
• Phase I/Ib study evaluating safety and efficacy of PRGN-3005 UltraCAR-T® (Autologous CAR T Cells) in advanced stage platinum resistant ovarian cancer patients. [cited 2022 Jul 28]. https://clinicaltrials.gov/ct2/show/NCT03907527
   Google Scholar
• Chiang C-L-L, Rovelli R, Sarivalasis A, et al. Integrating cancer vaccines in the standard-of-care of ovarian cancer: translating preclinical models to human. Cancers (Basel). 2021;13(18):4553.
   PubMed Web of Science ®Google Scholar
• Hardwick NR, Frankel P, Ruel C, et al. p53-reactive T cells are associated with clinical benefit in patients with platinum-resistant epithelial ovarian cancer after treatment with a p53 vaccine and gemcitabine chemotherapy. Clin Cancer Res. 2018;24(6):1315–1325.
   PubMed Web of Science ®Google Scholar
• P53MVA and pembrolizumab in treating patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. NCT03113487.
   Google Scholar
• Keskin DB, Anandappa AJ, Sun J. et al.Neoantigen vaccine generates intratumoral T cell r esponses in phase Ib glioblastoma trial. Nature. 2019;565(7738):234–239.
   PubMed Web of Science ®Google Scholar
• A phase 1, multicentre, open-label,nonrandomised, first-in-human study of OVM-200 as a therapeutic vaccine in patients with locally advanced or metastatic non-small cell lung cancer, ovarian cancer, and prostate cancer. [cited 2022 Jul 28]. https://clinicaltrials.gov/ct2/show/NCT05104515
   Google Scholar
• Randomized phase II study comparing neo-epitope based vaccine OSE2101 (TEDOPI®) with or without Anti-PD1 (Pembrolizumab) Versus best supportive care as maintenance treatment in platinum-sensitive recurrent ovarian cancer patient with controlled disease after platinum-based chemotherapy [cited 2022 Jul 28]. https://clinicaltrials.gov/ct2/show/NCT04713514
   Google Scholar
• Bjerregaard A-M, Nielsen M, Jurtz V, et al. An analysis of natural, T cell responses to predicted tumor neoepitopes. Front Immunol. 2017;8:1566.
   PubMed Web of Science ®Google Scholar
• A phase I trial evaluating a mutanome-directed immunotherapy in patients with high grade serous carcinoma (HGSC) of the ovary, fallopian tube or peritoneum. NCT03839524. • The first trial studying a personalized vaccine based on a panel of patient-specific mutations that were identified through artificial intelligence
   Google Scholar
• A phase II trial of oncolytic vaccinia virus (Olvi-Vec) primed immunochemotherapy in platinum-resistant/refractory ovarian cancer concluded for an ORR of 54% and an OS exceeding historical comparisons in heavily pretreated patients (Annals of Oncology. 2020;31(suppl_4):S551–S589. doi: 10.1016/annonc/annonc276)
   Google Scholar
• A randomized phase 3 study assessing the efficacy and safety of olvi-vec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer. NCT05281471).
   Google Scholar
• McMullen M, Karakasis K, Madariaga A, et al. Overcoming platinum and PARP-inhibitor resistance in ovarian cancer. Cancers (Basel). 2020 Jun 17;12(6):1607. PMID: 32560564; PMCID: PMC7352566.
   PubMed Web of Science ®Google Scholar
• Bartoletti M, Musacchio L, Giannone G, et al. Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors. Cancer Treat Rev. 2021Dec;101:102298. DOI:10.1016/j.ctrv.2021.102298
   PubMed Web of Science ®Google Scholar
• Musella A, Vertechy L, Romito A, et al. Bevacizumab in ovarian cancer: state of the art and unanswered questions. Chemotherapy. 2017;62(2):111–120. PMID: 27794568
   PubMed Web of Science ®Google Scholar
• Li J, Wang J, Chen R, et al. The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer. Oncotarget. 2017 Feb 28;8(9):15621–15631. PMID: 28152503; PMCID: PMC5362510.
   PubMedGoogle Scholar